Indonesia Pharma and Healthcare Sector Report 2024-2025

A decade after Indonesia's government launched its comprehensive public health insurance programme, the Jaminan Kesehatan Nasional (JKN), the scheme has reached 90% of the population by end-2022. The progressive rollout of this programme has allowed more Indonesians to afford modern healthcare services, motivating healthcare providers to build additional capacity to cater for the increased demand. The healthcare system relies heavily on imported medical devices and pharmaceuticals because domestic producers cannot manufacture many critical supplies that hospitals and clinics require. The Indonesian government has recently implemented policies to liberalise the investment environment to encourage foreign companies to set up production facilities in Indonesia, thereby reducing import dependence.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Indonesia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Indonesia
• Crystallise the forces both driving and restraining this sector in Indonesia
• Ascertain Indonesia’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Indonesia.
• Build a clear picture of trends, output and consumption for specific sub-sectors